PIK3CD and breast carcinoma: To investigate the efficacy of the PI3K inhibitor and its association with different mutations in the PI3K pathway, we combined tamoxifen (0–16 μM) with alpelisib (0–10 μM) at a constant ratio to assess the effect on breast cancer cell lines harboring different PIK3CA pathway alterations.